Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis

[1]  Jong-Suk Kim,et al.  Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells , 2022, Scientific Reports.

[2]  H. Nagano,et al.  Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells , 2022, BMC cancer.

[3]  Jie He,et al.  Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial , 2021, Cancer medicine.

[4]  Xiaoxin L Chen,et al.  Research on esophageal cancer: With personal perspectives from studies in China and Kenya , 2020, International journal of cancer.

[5]  Ying Zhang,et al.  Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways , 2020, OncoTargets and therapy.

[6]  Rongrong Chen,et al.  Combined treatment with anlotinib and chemotherapy for advanced esophageal squamous cell carcinoma improved patient survival: a case report. , 2020, American journal of translational research.

[7]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Rubini,et al.  Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. , 2020, Cancer biotherapy & radiopharmaceuticals.

[9]  Qin Li,et al.  Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy , 2019, Bioscience, biotechnology, and biochemistry.

[10]  H. Ge,et al.  Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities , 2019, OncoTargets and therapy.

[11]  R. Roskoski.  Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. , 2018, Pharmacological research.

[12]  Yuan Wang,et al.  Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel , 2018, Cell cycle.

[13]  Xiaojun Yao,et al.  Astragalus polysaccharide enhanced antitumor effects of Apatinib in gastric cancer AGS cells by inhibiting AKT signalling pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  M. Zheng,et al.  Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor , 2018, Cancer science.

[15]  Y. Li,et al.  Transcriptional Regulation of the Warburg Effect in Cancer by SIX1. , 2018, Cancer cell.

[16]  Yu-Shang Yang,et al.  Esophageal luminal stenosis is an independent prognostic factor in esophageal squamous cell carcinoma , 2017, Oncotarget.

[17]  F. Du,et al.  Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors , 2016, Journal of Hematology & Oncology.

[18]  Guoping Sun,et al.  Thioridazine Sensitizes Esophageal Carcinoma Cell Lines to Radiotherapy-Induced Apoptosis In Vitro and In Vivo , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[19]  Weijie Cao,et al.  Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways. , 2016, European journal of pharmacology.

[20]  Liang Zhao,et al.  Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest , 2016, Oncology research.

[21]  S. Barry,et al.  Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo , 2016, Science Translational Medicine.

[22]  M. Barbacid,et al.  Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma , 2016, Nature Medicine.

[23]  Napoleone Ferrara,et al.  Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.

[24]  K. Chan,et al.  Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy , 2014, Oncotarget.

[25]  S. Qin,et al.  Raltitrexed induces mitochondrial‑mediated apoptosis in SGC7901 human gastric cancer cells. , 2014, Molecular medicine reports.

[26]  G. Fasola,et al.  Clinical advances in the development of novel VEGFR2 inhibitors. , 2014, Annals of translational medicine.

[27]  Paul W Brown,et al.  Expression of Proto-Oncogene cFMS Protein in Lung, Breast, and Ovarian Cancers , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[28]  M. Harrison,et al.  Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. , 2013, European journal of cancer.

[29]  M. Joerger,et al.  Cancer chemotherapy: targeting folic acid synthesis , 2010, Cancer management and research.

[30]  M. Saif,et al.  Fluoropyrimidine-associated cardiotoxicity: revisited , 2009 .

[31]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[32]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Jansen,et al.  Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. , 2005, European journal of cancer.

[34]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[35]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[36]  H. Yamana,et al.  Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.